Pharmacy has been frozen for ages at direct chemical exploitation of new compoundswhich caused fluctuating efficiencies, side effectsand costs. However, nature is so specified in how diseases and pathogens evolve, and so we have to be in drug development. Cancer is our era’s epidemic nightmare, always evolving and developing resistance against any treatment in use forcing the use of drug combinationsraising complications at the cost of the patient’s body. Development of multi-pathway therapy helps keep the efficiency of multi drugs at low side effects and cost. We conducted cancer research using wiskostatin, which we claim to have multi-pathway and high selectivity for cancerous cells. Our IC50 and cancer resistance results assure wiskostatin is highly efficient compared to other drugs.


Seif Aser Rady

Mohamed Mahmoud